Elsevier

Clinical Therapeutics

Volume 31, Issue 11, November 2009, Pages 2608-2617
Clinical Therapeutics

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

https://doi.org/10.1016/j.clinthera.2009.10.020Get rights and content

Abstract

Objectives: The aims of this study were to estimate the proportion of patients with type 2 diabetes mellitus (DM) in the United States with different stages of chronic kidney disease (CKD) and to describe glycemic control and antidiabetic drug use among them.

Methods: Using data from the Fourth National Health and Nutrition Examination Survey (NHANES IV) for the years 1999 through 2004, we performed a crosssectional analysis of patients with type 2 DM aged ≥20 years at the time of the survey interview. CKD stages were categorized according to the classification system established by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Anti-diabetic medication use among these patients was described using self-reported survey responses as well as survey medication files.

Results: A total of 1462 patients with type 2 DM were included in the analysis. Men and women constituted 48.3% and 51.7% of the study sample, respectively; 15.6% received a DM diagnosis <2 years ago, and 36.2% received their diagnosis >10 years ago. CKD was present in 39.7% of patients with DM. Mean (SE) glycosylated hemoglobin was lower in more advanced CKD stages, from stage 1 (8.35% [0.23%]) to combined stages 4 and 5 (6.63% [0.15%]). Based on the medication file data, the proportion of patients with CKD using 1 antidiabetic medication was higher as CKD progressed, from 36.3% at stage 1 to 62.9% at stages 4 and 5 (P = 0.007). By self-report, the proportion of patients with CKD using insulin alone was 6.7% at stage 1 and 38.8% at stages 4 and 5 (P < 0.001). The proportion of patients using oral antidiabetic agents alone was 69.0% at stage 1 and 43.4% at stages 4 and 5 (P < 0.001).

Conclusions: Our results indicate that 39.7% of adult patients with type 2 DM in the United States had some degree of CKD, as measured in NHANES IV for the years 1999 through 2004. This finding reinforces the need to screen patients with type 2 DM for CKD and to prevent the cascade of events leading to nephropathy by implementing adequate glycemic and blood pressure controls, especially in the early stages of CKD. Our data also reinforce the need for developing more oral antidiabetic therapies for patients with advanced CKD and type 2 DM, because treatment options for this group are limited.

References (20)

  • E Selvin et al.

    Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004

    Am J Kidney Dis

    (2007)
  • CH Lin et al.

    A community-based study of chronic kidney disease among type 2 diabetics in Kinmen, Taiwan

    Diabetes Res Clin Pract

    (2007)
  • Chronic kidney disease

  • AS Narva et al.

    Chronic kidney disease: Definition and classification

  • Diabetes and chronic kidney disease: Stages 1–4

  • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification

    Am J Kidney Dis

    (2002)
  • J Coresh et al.

    Prevalence of chronic kidney disease in the United States

    JAMA

    (2007)
  • AS Levey et al.

    A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation

    Ann Intern Med

    (1999)
  • AS Levey et al.

    Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate [published correction appears in Ann Intern Med. 2008;149:519]

    Ann Intern Med

    (2006)
  • National health and nutrition examination survey codebook for data production (2005–2006)

There are more references available in the full text version of this article.

Cited by (115)

  • Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India

    2021, Endocrine and Metabolic Science
    Citation Excerpt :

    This also explains higher weight gain in ACCORD trial where there were more HEs. Renal disease is the most frequent T2DM complication and affects pharmacokinetic and pharmacodynamic profile of glucose-lowering agents (Bilous, 2008; Gross et al., 2005; Koro et al., 2009). Thus, preventing renal complications is one of the major concerns of T2DM pharmacotherapy.

View all citing articles on Scopus
View full text